Peptide & Experimental

Metformin

Biguanide / AMPK activator (indirect) · Glucophage, Siofor

Metformin is a biguanide and has been a standard drug for type 2 diabetes for decades. The longevity claim is something else: the study that would decide it has no results yet, and two training studies came out against metformin.

What metformin is

Metformin mildly inhibits mitochondrial complex I. This leads to activation of the energy sensor AMPK, inhibition of the growth signal mTOR and improved insulin sensitivity. Because exercise and fasting touch the same switches, the substance is regarded in the longevity scene as an exercise mimetic.

This very comparison is the point of contention. The mechanism is well understood, but it says nothing about whether the same effect occurs in healthy people or whether it is even desirable there.

What the data apply to

The large trial in people without diabetes studied people with prediabetes and obesity, not healthy people with normal glucose metabolism. Improved insulin sensitivity is also a surrogate marker - a lab value, not a course of disease.

On the question of whether metformin slows aging in humans, no completed human trial exists so far.

What is well supported

The largest trial in people without diabetes shows a clear risk reduction. In the Diabetes Prevention Program, metformin lowered diabetes incidence by 31 percent (95% CI 17-43) over 2.8 years in 3,234 people with elevated fasting and post-load glucose (mean age 51 years, BMI 34), from 11.0 to 7.8 cases per 100 person-years.
Approved for type 2 diabetes for decades. For this indication, there are endpoint data and comprehensive pharmacovigilance. The prevention trial used 850 mg twice daily, a usual dose; over three years, 13.9 people had to be treated to prevent one case of diabetes.
The pathway is described. Metformin mildly inhibits mitochondrial complex I, which leads to AMPK activation and mTOR inhibition. What has been clinically confirmed from this so far is the effect on glucose metabolism, tested over 2.8 years in prediabetes with obesity.
The longevity question is to be tested prospectively, with a defined endpoint. TAME was accepted by the FDA as the first prospective trial with aging as a composite multidisease endpoint. The trial is planned but has not started; no results are available.

What the studies show

Diabetes Prevention Program: effective, but lifestyle was better

Knowler 2002 randomized 3,234 people with elevated fasting and post-load glucose (mean age 51 years, BMI 34) to 850 mg metformin twice daily, placebo or a lifestyle program; follow-up 2.8 years. Diabetes incidence was 11.0 (placebo), 7.8 (metformin) and 4.8 (lifestyle) cases per 100 person-years. Metformin lowered the risk by 31 percent in relative terms (95% CI 17-43), lifestyle by 58 percent (48-66). Over three years, 13.9 people had to be treated with metformin to prevent one case, versus 6.9 in the lifestyle arm.

Endurance training: metformin blunted the adaptation

Konopka 2019 randomized 53 people with a mean age of 62 years, double-blind, to metformin or placebo and had them complete twelve weeks of aerobic endurance training. Metformin blunted the training-induced rise in insulin sensitivity and VO2max and abolished the rise in muscle mitochondrial respiration. In the metformin group, insulin sensitivity did not improve overall. Point estimates are not reported in the abstract.

MASTERS: placebo did better

Walton 2019 randomized 94 healthy people aged 65 and older, double-blind and placebo-controlled (metformin 1,700 mg per day, n=46; placebo n=48), and had them complete 14 weeks of progressive resistance training. The placebo group gained more fat-free mass (p=0.003) and more thigh muscle mass (p below 0.001) than the metformin group. Thigh area (p=0.005) and density (p=0.020) on CT also rose more on placebo. The strength gain tended to be blunted, without significance.

TAME: planned, no results

TAME (Targeting Aging with Metformin) was accepted by the FDA as the first prospective trial with aging as a composite multidisease endpoint. The trial is planned but has not started and accordingly has no results. The longevity narrative around metformin in humans therefore rests so far on observational data and mechanism, not on a completed randomized trial on aging.

Frailty: first randomized trial, so far only as a preprint

A randomized, double-blind trial gave 145 older people with impaired glucose tolerance metformin or placebo for 2 years. On the main measure, the Fried frailty score, values worsened on metformin in the first year, which was due to weight loss; without this criterion, there was no difference. A second measure, a frailty index of 95 individual deficits, worsened more slowly on metformin, and two epigenetic clocks showed a slightly lower biological age. The work is so far a preprint (medRxiv, July 2026) and not peer-reviewed. It is an indication, not proof, and does not replace a trial such as TAME.

Where the data stop

That metformin slows aging in humans. The trial meant to answer this question is still pending. Until then, there is no verified human trial for it.
That metformin works with normal glucose metabolism. The prevention data come from a population with prediabetes and obesity. They cannot be transferred to metabolically healthy people.
That metformin supports training gains. Two randomized trials found the opposite: blunted endurance adaptation and a smaller gain in muscle mass than on placebo.

Status, approval and legal

In Germany, metformin is prescription-only and approved for type 2 diabetes. For this indication, there are decades of endpoint data and comprehensive pharmacovigilance. Any use for life extension or to slow aging is off-label and not covered by any approval.

Safety

Gastrointestinal complaints are common at the start; with long-term use, vitamin B12 status needs attention. The most important safety aspect for this page, however, is not a classic side-effect finding: in two randomized training trials, training adaptation was weaker on metformin than on placebo.

BK-Score Well supported, heavily overhyped

Human evidence		8
Mechanism		8
Safety data		9
Hype gap		5
Track record of use		10

Approved for type 2 diabetes for decades, with endpoint data and comprehensive pharmacovigilance. The longevity claim is something else: the study that would decide it is not completed, and there are indications that metformin blunts training adaptations.

The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless. “Track record of use 9” means used long and widely – that is not proof of efficacy.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)

Frequently asked questions about Metformin

Does metformin slow aging?

That has not been shown in humans. The TAME trial, which is meant to test aging as a composite endpoint, is planned but has not started and has not reported any results. All longevity claims so far rest on observational data and the mechanism, not on a completed randomized trial in humans.

Does metformin hold back training gains?

Two randomized trials point that way. In 14 weeks of resistance training, the placebo group gained more fat-free mass and more thigh muscle mass than the metformin group. In twelve weeks of endurance training, metformin blunted the rise in insulin sensitivity and VO2max and abolished the rise in mitochondrial respiration.

Does metformin work in metabolically healthy people?

There are no robust data on this. The large prevention trial studied people with elevated glucose levels and an average BMI of 34, that is, prediabetes with obesity. Findings from this group cannot be transferred to people with normal glucose metabolism. Whether metformin has any effect at all there is open.

Is metformin approved in Germany?

Metformin is prescription-only and approved for type 2 diabetes. For this indication, there are decades of endpoint data and comprehensive pharmacovigilance. Use for life extension or to slow aging, by contrast, is off-label and not covered by any marketing authorization under medicines law. Off-label means treatment outside the tested and approved indication.

What are the side effects of metformin?

Gastrointestinal complaints are common at the start of treatment, and with long-term use, vitamin B12 status needs attention. In addition, there is a finding from two randomized trials that counts as an effect rather than a side effect: adaptation to resistance and endurance training was weaker on metformin.

What is the TAME trial?

TAME stands for Targeting Aging with Metformin. It was accepted by the FDA as the first prospective trial to test aging as a composite multidisease endpoint. The trial is planned but has not started and has not published any results. It is often cited as if it already provided proof, which is not the case.

The podcast episode (in German)

Episode 23

Metformin: the diabetes classic as an anti-aging hope, fact-checked

The podcast by Paul Höser (Episode 23). AI-generated German episode, inspired by several podcasts and supplemented with expert research. A solid, cheap, approved diabetes drug that, via the AMPK switch, targets the same aging pathways as exercise/fasting. But: longevity in healthy people is a hypothesis (TAME trial still open, ~2026/27), with a real downside – metformin can slow training/muscle gains. Plus the risk of B12 deficiency. Information only, not medical advice, no dosage or usage recommendation – prescription-only.

Listen on Spotify

Same topic area: metabolic pathwayRapamycin (Sirolimus)
Related topicHGH (Growth Hormone / Somatropin)
Same sectionMOTS-c
Same sectionSemaglutide (Ozempic / Wegovy)
Same sectionMK-677 (Ibutamoren)
ComparisonMetformin vs. Rapamycin (Sirolimus)

Sources

Open in the database – with search, filters and comparison (German app)

Information only, not medical advice and no usage or dosing recommendation. Prescription-only and unapproved substances belong in medical hands. Last updated: 2026-10-04.